Название продукции:(R)-6-tert-Butyl 4a-methyl 1-(4-fluorophenyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isoquinoline-4a,6(4H)-dicarboxylate

IUPAC Name:6-tert-butyl 4a-methyl (4aR)-1-(4-fluorophenyl)-1H,4H,4aH,5H,6H,7H,8H-pyrido[3,4-f]indazole-4a,6-dicarboxylate

CAS:864972-21-4
Молекулярная формула:C23H26FN3O4
Чистота:97%
Номер в каталоге:CM227405
Молекулярная масса:427.48

Упаковочная единица Доступно для заказа Цена ($) Количество

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:864972-21-4
Молекулярная формула:C23H26FN3O4
Точка плавления:-
Smiles-код:O=C([C@]12CC3=C(N(C4=CC=C(F)C=C4)N=C3)C=C1CCN(C(OC(C)(C)C)=O)C2)OC
Плотность:
Номер в каталоге:CM227405
Молекулярная масса:427.48
Точка кипения:
Номер Mdl:
Хранение:

Column Infos

Relacorilant
Corcept completes enrollment in phase 3 Gradient trial of Relacorilant in patients with Adrenal Cushing’s Syndrome. Cushing's disease or hypercortisolism is a rare endocrine disorder that occurs when a pituitary adenoma makes excessive cortisol. Cortisol exerts its functions by binding to the glucocorticoid receptor (GR).
Relacorilant is a selective glucocorticoid receptor modulator (SGRM) in clinical development to prevent the effects of high cortisol. Relacorilant is being studied in various serious disorders, including ovarian, adrenal and prostate cancer and Cushing’s syndrome.